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Background: Atorvastatin has been shown to improve cardiovascular risk (CVR) indices
in women with polycystic ovary syndrome (PCOS). Low-grade chronic inflammation
of adipose tissue may link PCOS and adverse CVR. In pro-inflammatory states such
as PCOS, spontaneous activation of the alternative pathway of complement results in
increased generation of acylation stimulating protein (ASP) from adipocytes irrespective
of body mass index.
Methods: The objective of this study was to determine the effect of atorvastatin on
markers of adipose tissue dysfunction and inflammation; acylation-stimulating-protein
(ASP), interleukin-6 (IL-6), and monocyte-chemoattractant-protein-1 (MCP-1) in
PCOS. This was a randomized, double-blind, placebo-controlled study where 40
medication-naive women with PCOS and biochemical hyperandrogenaemia were
randomized to either atorvastatin 20mg daily or placebo for 12 weeks. Following the
12 week randomization; both group of women with PCOS were subsequently started
on metformin 1,500mg daily for further 12 weeks to assess whether pre-treatment with
atorvastatin potentiates the effects of metformin on markers of adipose tissue function
We conducted a post-hoc review to detect plasma ASP and the pro-inflammatory
cytokines IL6 and MCP-1 before and after 12 and 24 weeks of treatment.
Results: There was significant reduction in ASP (156.7 ± 16.2 vs. 124.4 ± 14.8 ng/ml
p <0.01), IL-6 (1.48 ± 0.29 vs.0.73 ± 0.34 pg/ml p = 0.01) and MCP-1 (30.4 ± 4.2
vs. 23.0 ± 4.5 pg/ml p = 0.02) after 12 weeks of atorvastatin that was maintained
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subsequently with 12 weeks treatment with metformin. There was a significant positive
correlation between ASP levels with CRP (p < 0.01), testosterone (p < 0.01) and
HOMA-IR (p < 0.01); IL-6 levels with CRP (p <0.01) and testosterone (p < 0.01) and
MCP-1 with CRP (p < 0.01); testosterone (p < 0.01) and HOMA-IR (p < 0.02).
Conclusions: This post-hoc analysis revealed that 12 weeks of atorvastatin
treatment significantly decreased the markers of adipose tissue dysfunction and
inflammation, namely ASP, IL-6 and MCP-1 in obese women with PCOS. Changes in
adipose tissue markers were significantly associative with substantial improvements in
HOMA-IR, testosterone and hs-CRP levels.
ISRCTN Number: ISRCTN24474824.
Keywords: atorvastatin, acylation-stimulating-protein, interleukin-6, monocyte-chemoattractant-protein-1,
adipose tissue, PCOS
INTRODUCTION
In sub-clinical? pro-inflammatory states, including polycystic
ovary syndrome (PCOS), spontaneous activation of the
alternative pathway of complement results in increased
generation of acylation stimulating protein (ASP) from
adipocytes irrespective of body mass index (BMI) (1, 2).
ASP is formed with the cleavage of Complement 3a,by
carboxypeptidase B, that removes arginine at the carboxy-
terminal generating C3adesArg (3). ASP contributes to storage
of energy as lipids within adipose tissue by augmenting
post-prandial triglyceride (TG) clearance, enhanced fatty
acid esterification to triglycerides and decreased lipolysis
through inhibiting hormone sensitive lipase (HSL), thereby
increasing insulin resistance (2, 4, 5). ASP impacts
fat storage by enhancing diacylglycerol acyltransferase
(DGAT) activity, the rate limiting step in TG synthesis,
stimulating glucose transporter GLUT4 translocation and
indirectly enhancing LPL (lipoprotein lipase) activity in
adipocytes (6, 7).
Moreover, ASP has been shown to be raised in other
insulin resistant states, such as diabetes and obesity, as well
as in cardiovascular disease and is reported to be positively
correlated to plasma triglycerides, LDL cholesterol and non-
esterified fatty acids (NEFA) all of which are common in
women with PCOS (5, 8). It has been suggested that high
levels of ASP found in PCOS represent an ASP-resistant
state, that is related to “adipose tissue dysregulation” which
subsequently leads to adipose tissue inflammation, insulin
resistance, and dyslipidemia in these patients (9). The suggested
possible underlying mechanism of ASP resistance in such
patients is reduced expression of C5L2 receptor on adipose
tissue (10, 11). Interestingly, this process of decreased C5L2
expression is enhanced further by increased fatty acids and
high inflammatory markers present in obesity. Further, raised
ASP levels itselfinduces pro-inflammatory state via increased
cytokine release, as evident by both in vitro and in vivo
studies (12, 13). The underlying molecular mechanisms of ASP
resistance involve down regulation of intracellular response
elements, especially AKT, PI3-kinase and PDK. These are
also vital components of insulin response, which could link
the development of insulin resistance in conditions such as
PCOS (14).
It is also well-established that women with PCOS have
underlying chronic low grade inflammation associated with
high levels of inflammatory markers especially interleukin-6 (IL-
6), macrophage chemoattractant protein-1 (MCP-1) and highly
sensitive C-reactive protein (hs-CRP)—that are independent of
obesity (15). Metformin has been shown to reduce markers
of inflammation, especially ASP levels, in non-obese PCOS
women (9, 16). We have shown previously that atorvastatin
therapy reduced the inflammatory marker (hs-CRP) and insulin
resistance, which were positively correlated with the reduction
in triglyceride levels (17). We hypothesized that the effect of
atorvastatin on measures of inflammation and insulin resistance
aremediated through changes in ASP that have not been explored
before in women with PCOS. Accordingly, this post-hoc analysis
was performed to investigate the effects of atorvastatin and
metformin on inflammatory markers, including ASP in a well-
characterized group of young overweight/obese females with
PCOS (17).
MATERIALS AND METHODS
The diagnosis of PCOS was based on all three diagnostic criteria
of the Rotterdam consensus, namely clinical and biochemical
evidence of hyperandrogenaemia (Ferriman-Gallwey score
>8; free androgen index >8, respectively), oligomenorrhea
or amenorrhea and polycystic ovaries on transvaginal
ultrasound (18). Non-classical 21-hydroxylase deficiency,
hyperprolactinaemia, Cushing’s disease and androgen-secreting
tumors were excluded by appropriate tests. All women gave
their written informed consent and the study was approved
by the South Humber Research Ethics committee, UK (REC
reference: 04/Q1105/60).
Forty medication naïve women with PCOS and biochemical
hyperandrogenaemia were randomized to atorvastatin 20mg
daily or placebo for 3 months (17). Following this, an extension
study for both PCOS groups of women was undertaken with
metformin 1,500mg daily after completing the initial 3 months
of atorvastatin or placebo (19). A Flow chart of participants
through the experimental protocol is provided within Figure 1.
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The purpose of the extension study was to see whether pre-
treatment with atorvastatin potentiates the effects of metformin
on measures of inflammation and adipose tissue dysfunction
Thirty-seven women (atorvastatin = 19; placebo = 18)
completed 6 months of this study. Compliance was monitored
by counting returned medication. The biochemical assays
undertaken were fully described in detail in previous publications
of this investigation (17, 19). The same population is used in both
this analysis and previous studies (17, 19).
ASP levels were measured in plasma C3 in plasma samples, in-
house plasma controls and standard ASP were PEG precipitated
(polyethylene glycol 8000, Fisher Scientific). The samples were
centrifuged and the supernatant was used to assay for ASP.
Plates were pre-coated with monoclonal anti-ASP antibody and
blocked with bovine serum albumin (BSA). PEG precipitated
plasma samples and in-house plasma controls were diluted 1:40
in phosphate-buffered saline (PBS) and added to the plate.
ASP standard was also added using a concentration curve
ranging from 0.156 to 10 ng/ml. After incubation, the plates were
washed and incubated with rabbit polyclonal anti-ASP antibody.
Subsequently, goat anti-rabbit IgG conjugated to horseradish
peroxidase (Sigma-Aldrich) was added. The color reaction was
initiated by the addition of ophenylenediaminedihydrochloride
(Sigma-Aldrich) and was stopped using 1.25M sulphuric acid.
Absorbance was read at 490 nm. The intra-assay (within run)
variation was 3.9%. IL-6, and MCP-1 were measured in plasma
using DuoSet ELISA development kits from R&D Systems
(Abingdon, UK). The intra-assay variation of IL-6 was 2.2% and
MCP-1 was 2.8%.
Statistical Analysis
The paired t-test was used to compare pre-post within group
changes for clinical, hormonal and metabolic variables. The
Wilcoxon signed rank test was applied to biochemical data that
violated the assumptions of a normal distribution assessed by
the Kolmogorov-Smirnov test. Between-group comparisons of
percent changes of each parameters before and after treatment
were performed using independent samples t-test. For all
analysis, a two-tailed P ≤ 0.05 was considered to indicate
statistical significance. Correlations of selected parameters were
analyzed by using Pearson correlation coefficient and linear
regression (forward stepwise regression). Statistical analysis was
performed using SPSS for Windows NT, version 19.0 (SPSS Inc.,
Chicago, IL). Data are reported as mean± SEM.
RESULTS
The mean age of women was 27.7 ± 1.4 years (atorvastatin
group 26.6 ± 1.2 vs. placebo group 28.8 ± 1.8; p = 0.44).
The BMI were comparable in both atorvastatin and placebo
groups (33.20 ± 1.4 vs. 33.92 ± 1.4 kg/m2, p = 0.62) (17).
There were no significant differences in baseline parameters
between the two groups. After 12 weeks of atorvastatin therapy,
there were significant reductions in total cholesterol (4.6 ±
0.2 vs. 3.4 ± 0.2 mmol/liter, p < 0.01), LDL-C (2.9 ± 0.2
vs. 1.8 ± 0.2 mmol/liter, p = 0.01), triglycerides (1.34 ± 0.08
vs. 1.08 ± 0.13 mmol/liter, p < 0.01), free androgen index
(FAI) (13.4 ± 0.6 vs. 8.7 ± 0.4, p < 0.01), total testosterone
(4.1 ± 0.2 vs. 2.9 ± 0.1 nmol/liter, p < 0.01), hs-CRP (4.9
± 1.4 vs. 3.4 ± 1.1 mg/liter, p ≤ 0.04) and insulin resistance
(as measured by homeostasis model assessment for insulin
resistance, HOMA-IR) (3.3 ± 0.4 vs. 2.7 ± 0.4) along with
significant increase in sex hormone binding globulin (SHBG)
(31.1 ± 1.0 vs. 35.3 ± 1.2 nmol/liter, p < 0.01). There were no
significant changes in any of these parameters in the placebo
group (17). There was a positive correlation between reduction
in HOMA-IR with improvements in FAI (r2 = 0.56; p < 0.04)
FIGURE 1 | Flow chart of participants through the study.
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and triglycerides (r2 = 0.68; p < 0.01) in the atorvastatin
group (17).
The baseline ASP, IL-6, and MCP-1 were comparable in
both groups (Table 1). There were significant reductions in
ASP (156.7 ± 10.2 vs. 124.4 ± 9.8 ng/ml; p < 0.01), IL-6
(1.48 ± 0.09 vs. 0.73 ± 0.10 pg/ml; p < 0.01) and MCP-1
levels (30.4 ± 1.2 vs. 23.0 ± 3.5 pg/ml p < 0.02) after 12
weeks of atorvastatin (Table 1). The decrease in ASP (124.4
± 14.8 vs. 119.5 ± 23.8 ng/ml p = 0.41), IL-6 (0.73 ±
0.34 vs. 0.74 ± 0.21 pg/ml p = 0.91), and MCP-1 (23.0 ±
4.5 vs. 23.9 ± 6.2 pg/ml p = 0.63) levels were maintained
following 12 weeks of metformin treatment. There were no
significant changes in ASP, IL-6, and MCP-1 levels in the
placebo group.
There were significant associations of ASP, IL-6, and MCP-1
with hs-CRP and testosterone levels. There were also substantial
correlations of ASP and MCP-1 with improvements in insulin
resistance (HOMA-IR); however, only ASP was shown to
have positive correlation with significant improvements in
triglycerides (Table 2).
On multiple linear stepwise regression analysis the changes
in ASP, IL-6, and MCP-1 accounted for 52% of the variance in
CRP and 46% of testosterone levels but only ASP and MCP-1
accounted for 40% of the variance in HOMA-IR (Table 3).
DISCUSSION
This post-hoc analysis revealed that 12 weeks of atorvastatin
treatment significantly decreased markers of adipose tissue
dysfunction and inflammation as determined by ASP, IL-6, and
MCP-1 in younger, overweight obese women with PCOS. These
improvements were that are related significantly with substantial
improvements in HOMA-IR, testosterone and hs-CRP levels.
In this study atorvastatin treatment improved ASP sensitivity
in PCOS women with hyperandrogenimia) as suggested by
significant reductions in ASP levels. This suggests a potentially
novel mechanism for the improved insulin sensitivity reflected
in the substantial decrease in HOMA-IR with associated
improvements in androgen levels and inflammatory markers.
In addition, reduction in ASP levels after by atorvastatin
treatment was associated (although not necessarily causal) with
significant improvement in dyslipidaemia in these women as
suggested by enhanced triglycerides clearance and reduced
cholesterol levels.
The reduction in ASP after 12 weeks of atorvastatin
treatment was associated with substantial improvements in
biochemical hyperandrogenaemia—the most distinctive feature
of PCOS. Additionally, low levels of SHBG also contribute
to high free testosterone levels by reducing binding with
testosterone (20). Several studies have reported that insulin
resistance with compensatory hyperinsulinaemia is the primary
underlying cause for hyperandrogenaemia in women with
PCOS. hyperandrogenaemia is induced by both decreased
hepatic production of SHBG levels and increased production
of androgens via ovaries and adrenal glands (21). This is
evident further from intervention trials improving insulin
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resistance in PCOS women using different therapies e.g., weight
loss, metformin, D-chiro-inositol and peroxisome proliferator-
activated receptor gamma (PPARÈ)-agonists demonstrating
reduced androgen levels with improved exaggerated androgenic
response to ACTH, or LH stimulation tests (22–24). However, the
underlyingmechanism related to improved hyperandrogenaemia
due to reduced insulin resistance has not been explained
completely. Our findings suggest that an improved ASP resistant
state and related intracellular pathways lead to improved insulin
sensitivity that subsequently reduce androgen levels. Our study
suggests the potential for novel treatment targets related to
modifying adipose tissue dysfunction for PCOS women in
the future.
Women with PCOS have elevated levels of hs-CRP that is an
independent risk marker of early cardiovascular disease (25).
TABLE 2 | Correlation coefficients between changes in ASP, IL-6, and MCP-1 and
changes in waist circumference, cholesterol, testosterone, hs-CRP, and HOMA
after atorvastatin treatment.
N = 19 Parameters Correlation coefficient P-value
1 ASP
1 Weight 0.13 0.59
1 Waist circumference 0.12 0.78
1 Total cholesterol 0.24 0.66
1 Triglycerides 0.32 0.04
1 Testosterone 0.66 <0.01
1 hs-CRP 0.52 0.01
1 HOMA-IR 0.59 <0.01
1 IL-6
1 Weight 0.12 0.96
1 Waist circumference 0.16 0.90
1 Total cholesterol 0.22 0.52
1 Triglycerides 0.12 0.33
1 Testosterone 0.49 0.01
1 hs-CRP 0.57 <0.01
1 HOMA-IR 0.19 0.27
1 MCP-1
1 Weight 0.20 0.34
1 Waist circumference 0.10 0.95
1 Total cholesterol 0.11 0.82
1 Triglycerides 0.22 0.79
1 Testosterone 0.41 0.01
1 hs-CRP 0.44 <0.01
1 HOMA-IR 0.36 0.02
There was 25% reduction in hs-CRP levels after atorvastatin
treatment in the present investigation. These changes were was
also positively correlated to ASP levels suggesting improvements
in underlying inflammatory environment coincided with
improved ASP sensitivity, although again, it is not possible to
state whether one directly impacted on the other. However,
these finding are consistent with previous studies aiming at
improving cardiovascular risk in women with PCOS using
several interventions including weight loss, metformin and
PPARÈ (26, 27).
The changes in ASP were not correlated with changes in
changes in total cholesterol and triglyceride suggesting that
the effects of atorvastatin in these inflammatory markers are
independent of its plasma lipid lowering effects. There is
increasing body of evidence that there are beneficial effects of
statin other than lipid lowering, or “pleotropic effects” including
improvement in endothelial dysfunction, increase nitric oxide
availability, antioxidant properties, inhibition of inflammatory
responses, and stabilization of atherosclerotic plaques (28). These
pleitropic effects could also be partly mediated through this effect
on ASP resistance.
ASP levels have been shown to be increased in patients with
obesity (4). In the current study both the groups are matched for
body mass and there were no significant changes in weight before
and after treatment with atorvastatin. This suggests that the effect
of atorvastatin in ASP levels in womenwith PCOS is independent
of changes in obesity status. This effect needs to be evaluated with
normal weight or less overweight women with PCOS.
In women with PCOS there is a significant increase
in proinflammatory cytokines especially IL-6 and MCP-1.
This again appears to be independent of body mass index
(29, 30). IL-6 is a potent inducer of hepatic CRP and
has been implicated in cardiovascular atherosclerotic risk,
dyslipidemia and hypertension (31). In this study there
was a 50% reduction in IL-6 after 12 weeks of atorvastatin
that correlated positively with reduction in CRP. The
reduction in IL-6 appeared to be independent of reduction
in total cholesterol and triglycerides with atorvastatin.
Furthermore, the reduction in IL-6 was not related to
changes in insulin resistance, suggesting reduction of ASP
by atorvastatin as the underlying mechanism for reducing
inflammatory markers.
It has been suggested that increased MCP-1 levels may
induce insulin resistance (32) which are increased in women
with PCOS compared with weight-matched controls (30,
33, 34). In this study, changes in MCP-1 levels correlated
TABLE 3 | Multiple linear stepwise regression model identifying independent predictors of changes in testosterone, hs-CRP, and HOMA-IR.
Dependent variable 1 Testosterone 1 hs-CRP 1 HOMA-IR
R2 (p-value) 0.46 (p = 0.01) 0.52 (p < 0.01) 0.40 (p = 0.03)
Independent variables 1 ASP (p < 0.01)
1 IL-6 (p = 0.001)
1 MCP-1(p = 0.02)
1 ASP (p = 0.01)
1 IL-6 (p < 0.01)
1 MCP-1 (p = 0.04)
1 ASP (p < 0.01)
1 MCP-1 (p = 0.015)
For dependent variables, 1 Testosterone, 1 hs-CRP, and 1 HOMA-IR were used. Independent variable included 1 ASP, 1 IL-6, and 1 MCP-1.
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significantly with changes in ASP levels and independently
predicted changes in HOMA-IR after atorvastatin therapy.
The reduction in pro-inflammatory cytokines and subsequent
insulin resistance could be due to improvement in underlying
ASP resistance.
The reduction in ASP, IL-6 and MCP-1 was maintained
after 12 weeks of metformin subsequent to atorvastatin therapy,
suggesting metformin have an effect in continued suppression
of these markers. Statins have also been shown to rapidly
activate AMP-activated protein kinase (AMPK), a protein kinase
that modulates metabolic homeostasis and energy balance in
individual cells and multiple organs, both in-vivo and in-vitro
(35). The actions of metformin also appear to be mediated
by AMPK activation (36) suggesting that this pathway is
independent of the ASP modulated effects.
In conclusion, 12 weeks of atorvastatin led to a significant
reduction the adipose tissue dysfunction marker ASP and in
adipocyte inflammation markers (IL-6 and MCP-1) in women
with PCOS. The changes in ASP levels after atorvastatin
treatment independently predicted changes in insulin resistance,
androgens, and inflammatory markers. Our findings suggest that
the effects of atorvastatin might be partly mediated through
reducing ASP in women with PCOS.
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